Earnings ·
Reports Q3 revenue of $832.5M and net income of $258.6M
UTHRUNITED THERAPEUTICS Corp
United Therapeutics reported third-quarter 2026 total revenues of $832.5 million, a 4% increase from the prior year period, driven by growth in Tyvaso DPI and Orenitram sales. Net income declined 24% to $258.6 million, or $5.71 per diluted share, compared to $338.7 million and $7.16 per diluted share in the same quarter of 2025. The earnings decline was primarily attributable to a significant increase in research and development expenses, which rose 119% year-over-year due to costs associated with the acquisition of Thymmune Therapeutics and manufactured organ projects. Additionally, the company finalized accelerated share repurchase agreements totaling approximately $1.98 billion during the quarter.